The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?
The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of [...]
Could Germany’s Proposed Drug Pricing Reform Impact United States?
The German committee responsible for assessing drug efficacy and setting prices may cut the initial 12-month review time by 50%. [...]
Pharma Price Negotiations and Reimbursement Hurdles in Germany
Negotiating the prices of Advanced Therapy Medicinal Products (ATMPs) is a challenging and convoluted process in Germany. The majority of [...]
HTA and Affordability for Innovative Therapies in Germany
A major challenge facing both HTA authorities and manufacturers is integrating new and innovative treatments into the healthcare system. A [...]
Germany’s Experiment With Drug Price Regulation: Aligning Clinical Benefit With Cost of Cancer Drugs
According to a new study, Germany’s move to reform pharmaceutical spending has resulted in closer alignment between clinical benefit and [...]
Advertisement
